Non–Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers

Semin intervent RadiolDOI: 10.1055/s-0033-1349396Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals:Table of contents  |  Full text
Source: Seminars in Interventional Radiology - Category: Radiology Authors: Tags: Erratum Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Lung cancer is one of the leading causes of death worldwide [1]. Approximately 80% of lung cancer patients are consistent with non-small cell histology (NSCLC) [2]. The Tumor-Node-Metastasis (TNM) system is used to classify and stratify patients by prognosis according to tumor size (T), lymph node (LN) involvement (N) and presence of distant metastases (M). Its actual valid 8th edition was implemented in 2016 using clinical information from 70,976 consecutive NSCLC patients treated between 1999 and 2010 in 16 countries [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractBackgroundIt is known that there are insufficient prognostic factors for non-small cell lung cancer (NSCLC). It was reported that PD-L1 was a prognostic factor for NSCLC,and c-Myc regulated the expression of PD-L1. Herein, we investigated c-Myc and PD-L1 expression and their association with overall survival (OS) in NSCLC.MethodsFormalin-fixed paraffin-embedded specimens were obtained from 128 patients with surgically resected primary NSCLC. Immunohistochemistry was used to assess the expression of PD-L1 and c-Myc in this study. Pearson ’s Chi squared test or Fisher’s exact test was used to analyze the ...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsA three-platelet mRNA set:MAX, MTURN and HLA-B enables blood-based lung cancer diagnosis and chemotherapy response prediction.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 October 2019Source: The Annals of Thoracic SurgeryAuthor(s): Melanie P. Subramanian, Graham A. Colditz
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Authors: Sano M, Kaneko MK, Kato Y Abstract The highly O-glycosylated membrane glycoprotein podoplanin (PDPN) is frequently overexpressed in several malignant cancers, such as oral cancer, lung cancer, germinal neoplasia, mesothelioma, and brain tumor. The expression of PDPN is strongly associated with cancer progression and poor prognosis. PDPN possesses three tandem repeats of platelet aggregation-stimulating (PLAG) domains (PLAG1, PLAG2, and PLAG3) and PLAG-like domain (PLD), and binds to C-type lectin-like receptor 2 (CLEC-2) on platelets, followed by PDPN-mediated platelet aggregation. We have previously estab...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
ConclusionsAt the current price of pemetrexed, the combination of pemetrexed plus cisplatin was not found to be a cost-effective first-line regimen for patients with non-small cell lung cancer at the local Thai threshold compared with the gemcitabine plus cisplatin and carboplatin plus paclitaxel regimens.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
CONCLUSION: Disease progression is an independent predictor with negative impact in overall survival. PMID: 31625877 [PubMed - in process]
Source: Acta Medica Portuguesa - Category: General Medicine Tags: Acta Med Port Source Type: research
Publication date: Available online 19 October 2019Source: Respiratory Medicine Case ReportsAuthor(s): V.R. Anjali, Rambha Pandey, Astha Srivastava, Madhu Rajeshwari, Durgatosh Pandey, M.C. SharmaAbstractWith the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell lung cancer are commonly EGFR (Epidermal Growth Factor Receptor) gene mutation and ALK (Anaplastic Lymphoma Kinase) gene rearran...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been developed for the treatment of EML4-ALK-rearranged non-small-cell lung cancer, with the newer generation agents brigatinib, alectinib and lorlatinib showing pronounced central nervous system activities. Intracranial efficacy is an important feature for these agents, as metastatic lesions frequently occur in the central nervous system in the ALK-positive setting. Here, we report on an updated case of a patient who received her diagnosis in 2005 and has had disease progression with new lesions on six occasions over the last 8 years. During the firs...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Radiology